These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1. Zhang J; Ali AM; Lieu YK; Liu Z; Gao J; Rabadan R; Raza A; Mukherjee S; Manley JL Mol Cell; 2019 Oct; 76(1):82-95.e7. PubMed ID: 31474574 [TBL] [Abstract][Full Text] [Related]
4. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262 [TBL] [Abstract][Full Text] [Related]
5. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases]. Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441 [No Abstract] [Full Text] [Related]
6. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A Elife; 2022 Aug; 11():. PubMed ID: 36040792 [TBL] [Abstract][Full Text] [Related]
7. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand. Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497 [TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334 [TBL] [Abstract][Full Text] [Related]
9. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. Mupo A; Seiler M; Sathiaseelan V; Pance A; Yang Y; Agrawal AA; Iorio F; Bautista R; Pacharne S; Tzelepis K; Manes N; Wright P; Papaemmanuil E; Kent DG; Campbell PC; Buonamici S; Bolli N; Vassiliou GS Leukemia; 2017 Mar; 31(3):720-727. PubMed ID: 27604819 [TBL] [Abstract][Full Text] [Related]
11. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis. Wang X; Song X; Yan X Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956 [TBL] [Abstract][Full Text] [Related]
12. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Obeng EA; Chappell RJ; Seiler M; Chen MC; Campagna DR; Schmidt PJ; Schneider RK; Lord AM; Wang L; Gambe RG; McConkey ME; Ali AM; Raza A; Yu L; Buonamici S; Smith PG; Mullally A; Wu CJ; Fleming MD; Ebert BL Cancer Cell; 2016 Sep; 30(3):404-417. PubMed ID: 27622333 [TBL] [Abstract][Full Text] [Related]
13. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Lieu YK; Liu Z; Ali AM; Wei X; Penson A; Zhang J; An X; Rabadan R; Raza A; Manley JL; Mukherjee S Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34930825 [TBL] [Abstract][Full Text] [Related]
14. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273 [TBL] [Abstract][Full Text] [Related]
15. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes. Madan V; Li J; Zhou S; Teoh WW; Han L; Meggendorfer M; Malcovati L; Cazzola M; Ogawa S; Haferlach T; Yang H; Koeffler HP Am J Hematol; 2020 Feb; 95(2):133-143. PubMed ID: 31680297 [TBL] [Abstract][Full Text] [Related]
16. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches. Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033 [TBL] [Abstract][Full Text] [Related]